Study finds five-minute weekly dose of peanut protein through the skin, delivered by a novel microneedle technology, was superior in desensitizing peanut-allergic mice compared to administering the protein through a skin patch.
If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.